News

| Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences Read more
Collaboration Brings Together Gilead’s Commitment to Advancing Cell Therapy with Kyverna’s Focus on Advanced T Cell Engineering Targeting Autoimmune Diseases Series A Investors Include Vida ... Read More